Clinical trials are needed; several are already underway, which could confirm our findings and investigate other unresolved issues, such as the optimal dose, type, and duration of SGLT2 inhibitor therapy to prevent CIN. The gene discussed is SLC5A2; the disease is cervical squamous intraepithelial neoplasia.